September 15, 2016 / 1:42 PM / a year ago

BRIEF-Aralez announces FDA approval of Yosprala for secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin-associated gastric ulcers

Sept 15 (Reuters) - Aralez Pharmaceuticals Inc

* Announces FDA approval of YOSPRALA for secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin associated gastric ulcers

* Aralez Pharmaceuticals Inc says YOSPRALA U.S. commercial launch planned for first week of october

* Each study achieved its individual primary endpoint

* Aralez Pharmaceuticals Inc says Aralez sales force will be expanded by 85 to 110 sales representatives by launch

* Says studies demonstrate yosprala clinical benefit Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below